Latest market price
87.03
+1.29+1.50%
Filing
Up 1.5% — Filed an 8-K material-event report (2026-11-03) — details in the filing.
Medium confidence
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -14.56 | Insider Own | 32.69% | Shs Outstand | 64.93M | Perf Week | 1.72% |
| Market Cap | 5.57B | Forward P/E | — | EPS next Y | -0.63 | Insider Trans | -0.85% | Shs Float | 53.79M | Perf Month | 6.88% |
| Enterprise Value | 5.89B | PEG | — | EPS next Q | -0.49 | Short Float | 12.39% | Perf Quarter | -17.73% | ||
| Income | -860.00M | P/S | 9.01 | EPS this Y | — | Short Ratio | 9.09 | Perf Half Y | -17.75% | ||
| Sales | 618.00M | P/B | — | EPS next Y | — | ROA | -82.32% | Short Interest | 6.66M | Perf YTD | 10.18% |
| Book/sh | -0.15 | P/C | 12.71 | EPS next 5Y | — | ROE | — | 52W High | 130.00 -33.05% | Perf Year | 19.79% |
| Cash/sh | 6.75 | P/FCF | — | EPS past 3/5Y | — | ROIC | -13.09% | 52W Low | 63.23 37.64% | Perf 3Y | 220.67% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | 89.14% — | Gross Margin | 81.70% | Volatility | 3.51% 4.39% | Perf 5Y | 450.82% |
| Dividend TTM | — | EV/Sales | 9.53 | EPS Y/Y TTM | — | Oper. Margin | -17.42% | ATR (14) | 3.49 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 2.74 | Sales Y/Y TTM | 44.06% | Profit Margin | -139.18% | RSI (14) | 53.04 | Recom | 1.94 |
| Dividend Gr. 3/5Y | — | Current Ratio | 2.86 | EPS Q/Q | -783.33% | SMA20 | 4.28% | Beta | 0.74 | Target Price | 153.20 |
| Payout | 0.00% | Debt/Eq | — | Sales Q/Q | 37.50% | SMA50 | -2.79% | Rel Volume | 0.88 | Prev Close | 85.74 |
| Employees | 433 | LT Debt/Eq | — | Earnings | Feb 24 | SMA200 | -11.66% | Avg Volume | 722.03K | Price | 87.03 |
| IPO Date | Jul 18, 2019 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -42.75% 5.93% | Net Debt/EBITDA | — | Volume | 634,968 | Change | 1.50% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-14-26 | Reiterated | Stifel Nicolaus | $136 → $156 | |
| Oct-13-26 | Reiterated | Evercore ISI Group | Outperform | $138 → $146 |
| Oct-12-26 | Reiterated | HC Wainwright & Co. | Buy | $195 → $200 |
| Oct-08-26 | Reiterated | RBC Capital | Outperform | $135 → $155 |
| Sep-29-26 | Reiterated | Robert W. Baird | $123 → $130 | |
| Sep-28-26 | Reiterated | Morgan Stanley | Overweight | $137 → $144 |
| Sep-28-26 | Reiterated | HC Wainwright & Co. | Buy | $140 → $195 |
| Aug-27-26 | Reiterated | UBS | $140 → $137 | |
| Aug-06-26 | Reiterated | Robert W. Baird | $129 → $123 | |
| Aug-06-26 | Reiterated | Morgan Stanley | Overweight | $150 → $137 |
Latest News· Times ET
Today
Nov-02-26
Nov-02-2608:02AM
Oct-28-26
Oct-28-2609:00AM
Oct-27-26
Oct-27-2611:06AM
Oct-26-26
Oct-26-2608:00AM
Oct-21-26
04:15AM
Oct-16-26
Oct-16-2602:59AM
Oct-15-26
Oct-15-2604:01PM
Oct-13-26
Oct-12-26
Oct-12-2612:42PM
11:02AM
Company
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 618 | 521 | 337 | 186 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 113 | 101 | 82 | 47 | — | — | — | — | — | |
| Gross Profit | 505 | 421 | 255 | 139 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 313 | 257 | 202 | 146 | — | — | — | — | — | |
| Research and Development | 283 | 186 | 141 | 103 | — | — | — | — | — | |
| Other Operating Expense | 16 | 0 | 0 | -1 | — | — | — | — | — | |
| Operating Income | -108 | -22 | -88 | -109 | — | — | — | — | — | |
| Interest Expense | 15 | 14 | 14 | 15 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -736 | 15 | 15 | -38 | — | — | — | — | — | |
| Net Income Before Taxes | -858 | -21 | -87 | -162 | — | — | — | — | — | |
| Income Taxes | 3 | 2 | 1 | 1 | — | — | — | — | — | |
| Consolidated Net Income | -860 | -23 | -88 | -163 | — | — | — | — | — | |
| Net Income From Continuing Operations | -860 | -23 | -88 | -163 | — | — | — | — | — | |
| Net Income | -860 | -23 | -88 | -163 | — | — | — | — | — | |
| EPS (Recurring) | -14.56 | -0.47 | -1.85 | -4.00 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -14.56 | -0.47 | -1.85 | -4.00 | — | — | — | — | — | |
| EPS (Diluted) | -14.56 | -0.47 | -1.85 | -4.00 | — | — | — | — | — | |
| EBITDA | -776 | 17 | -49 | -136 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 8.87 | 7.58 | 5.89 | 6.51 | — | — | — | — | — | |
| Gross Margin | 81.72 | 80.81 | 75.67 | 74.73 | — | — | — | — | — | |
| Operating Margin | -17.48 | -4.22 | -26.11 | -58.60 | — | — | — | — | — | |
| Net Margin | -139.16 | -4.41 | -26.11 | -87.63 | — | — | — | — | — | |
| Shares Outstanding | 63 | 50 | 48 | 41 | — | — | — | — | — | |
| Market Capitalization | 5,483 | 3,949 | 1,985 | 1,210 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Howe Jolanda | SVP, GLOBAL CONTROLLER | Oct 16 '26 | Option Exercise | 19.24 | 16,112 | 309,995 | 16,728 | Oct 19 |
| Peetz Christopher | CHIEF EXECUTIVE OFFICER | Oct 06 '26 | Option Exercise | 17.31 | 12,197 | 211,179 | 206,637 | Oct 06 |
| BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | Sep 14 '26 | Sale | 98.37 | 9,943 | 978,093 | 44,745 | Sep 15 |
| BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | Sep 11 '26 | Option Exercise | 0.00 | 18,333 | 0 | 54,688 | Sep 15 |
| Howe Jolanda | SVP, GLOBAL CONTROLLER | Sep 02 '26 | Sale | 100.00 | 658 | 65,800 | 616 | Sep 03 |
| Peetz Christopher | CHIEF EXECUTIVE OFFICER | Sep 01 '26 | Option Exercise | 2.94 | 30,000 | 88,080 | 224,440 | Sep 03 |
| Peetz Christopher | CHIEF EXECUTIVE OFFICER | Sep 01 '26 | Sale | 98.68 | 30,000 | 2,960,401 | 194,440 | Sep 03 |
| Howe Jolanda | SVP, GLOBAL CONTROLLER | Aug 18 '26 | Option Exercise | 6.27 | 40,000 | 250,800 | 41,274 | Aug 19 |
| Howe Jolanda | SVP, GLOBAL CONTROLLER | Aug 18 '26 | Sale | 100.00 | 40,000 | 4,000,000 | 1,274 | Aug 19 |
| BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | Aug 11 '26 | Sale | 99.90 | 6,001 | 599,510 | 36,355 | Aug 12 |
| Peetz Christopher | CHIEF EXECUTIVE OFFICER | Aug 10 '26 | Sale | 98.92 | 20,000 | 1,978,401 | 194,309 | Aug 11 |
| Peetz Christopher | CHIEF EXECUTIVE OFFICER | Aug 10 '26 | Option Exercise | 2.94 | 20,000 | 58,720 | 214,309 | Aug 11 |
| Howe Jolanda | SVP, GLOBAL CONTROLLER | Aug 03 '26 | Sale | 105.29 | 1,840 | 193,734 | 1,274 | Aug 05 |
| Peetz Christopher | CHIEF EXECUTIVE OFFICER | Jul 06 '26 | Option Exercise | 2.94 | 20,000 | 58,720 | 214,309 | Jul 08 |
| Peetz Christopher | CHIEF EXECUTIVE OFFICER | Jul 06 '26 | Sale | 122.27 | 20,000 | 2,445,383 | 194,309 | Jul 08 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.